Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
87.4M
-
Number of holders
-
126
-
Total 13F shares, excl. options
-
83.1M
-
Shares change
-
-33.7K
-
Total reported value, excl. options
-
$310M
-
Value change
-
+$2.35M
-
Put/Call ratio
-
0.52
-
Number of buys
-
70
-
Number of sells
-
-62
-
Price
-
$3.73
Significant Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) as of Q2 2025
163 filings reported holding TERN - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q2 2025.
Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) has 126 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 83.1M shares
of 87.4M outstanding shares and own 95.14% of the company stock.
Largest 10 shareholders include Soleus Capital Management, L.P. (8.17M shares), ORBIMED ADVISORS LLC (7.56M shares), Deep Track Capital, LP (7.5M shares), MORGAN STANLEY (7.25M shares), Vivo Capital, LLC (6.9M shares), BlackRock, Inc. (5.47M shares), VANGUARD GROUP INC (4.31M shares), CITADEL ADVISORS LLC (3.9M shares), Schonfeld Strategic Advisors LLC (3.05M shares), and Candriam S.C.A. (2.37M shares).
This table shows the top 126 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.